Head-To-Head Contrast: BioNexus Gene Lab (NASDAQ:BGLC) & Agilon Health (NYSE:AGL)

BioNexus Gene Lab (NASDAQ:BGLC) and Agilon Health (NYSE:AGL) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, profitability, analyst recommendations and earnings.

Analyst Ratings

This is a summary of recent ratings and target prices for BioNexus Gene Lab and Agilon Health, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNexus Gene Lab	1	0	0	0	1.00
Agilon Health	2	8	5	0	2.20

Agilon Health has a consensus price target of $58.73, suggesting a potential downside of 51.19%. Given Agilon Health’s stronger consensus rating and higher possible upside, analysts plainly believe Agilon Health is more favorable than BioNexus Gene Lab.

Valuation & Earnings

This table compares BioNexus Gene Lab and Agilon Health”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNexus Gene Lab	$7.43 million	0.67	-$2.98 million	($1.48)	-1.38
Agilon Health	$5.93 billion	0.34	-$391.35 million	($21.56)	-5.58

BioNexus Gene Lab has higher earnings, but lower revenue than Agilon Health. Agilon Health is trading at a lower price-to-earnings ratio than BioNexus Gene Lab, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

18.9% of BioNexus Gene Lab shares are held by institutional investors. 0.1% of BioNexus Gene Lab shares are held by company insiders. Comparatively, 2.3% of Agilon Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares BioNexus Gene Lab and Agilon Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioNexus Gene Lab	-54.70%	-37.43%	-32.88%
Agilon Health	-6.09%	-146.03%	-24.55%

Volatility & Risk

BioNexus Gene Lab has a beta of 4.06, indicating that its stock price is 306% more volatile than the S&P 500. Comparatively, Agilon Health has a beta of 3, indicating that its stock price is 200% more volatile than the S&P 500.

About BioNexus Gene Lab

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

About Agilon Health

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. agilon health, inc. was founded in 2016 and is based in Austin, Texas.